ArticleCancer medicine2026
Association of Lipid and Inflammatory Profiles With Tumor Stage in Hepatocellular Carcinoma.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Inflammatory responses and lipid metabolism disorders are known to influence cancer development; however, their combined effects on HCC progression remain unclear. This study examined the associations between lipid profiles and inflammatory markers with HCC stage.
methodsIn this cross-sectional study, data from 90 patients with HCC and available Barcelona Clinic Liver Cancer stage information were analyzed. Serum lipid profiles and inflammatory markers were measured, and derived indicators-including non-high-density lipoprotein cholesterol (non-HDL-C), the low-density lipoprotein cholesterol (LDL-C)-to-HDL-C ratio, the total cholesterol (TC)-to-HDL-C ratio, and the neutrophil-to-HDL-C ratio (NHR)-were calculated. Correlation analysis and logistic regression were performed with adjustment for potential confounders. Interaction analysis was conducted to examine relationships among lipid-inflammatory profiles, with findings validated in an independent cohort of 200 patients with HCC.
resultsHDL-C levels were significantly lower in patients with non-advanced stage tumors (0.81 ± 0.27 vs. 1.15 ± 0.28, p < 0.01). HDL-C showed a positive correlation with tumor stage (r = 0.544, p < 0.01), whereas non-HDL-C, LDL-to-HDL ratio, TC-to-HDL ratio, and NHR demonstrated negative correlations (r = -0.269, -0.568, -0.382, and -0.432, respectively; all p < 0.05). In univariate logistic regression analysis, higher LDL-to-HDL ratio (odds ratio [OR] = 0.193, 95% confidence interval [CI]: 0.066-0.562) and higher TC-to-HDL ratio (OR = 0.378, 95% CI: 0.195-0.730) were significantly associated with non-advanced stage, and these associations persisted after adjustment for NHR.
conclusionsLipid-inflammatory profiles were associated with HCC staging in correlation and partially adjusted regression analyses and showed apparent discriminative performance in ROC analysis. However, no independent predictors were identified in the fully adjusted multivariable model. These findings should be considered exploratory and hypothesis-generating, suggesting that lipid-inflammatory profiles may reflect staging-related metabolic and inflammatory alterations rather than serve as independent staging markers. Further validation in large prospective studies is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.